Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone for Myocardial Fibrosis After AMI
NCT05531955Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirfenidone in myocardial fibrosis, sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
pirfenidone
03
Conditions
myocardial fibrosis
Beyond the preview
Go deeper on NCT05531955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05531955.